source
- Abbott to pay $385 million to settle claims over 2022 baby-formula plant shutdownAbbott Laboratories agreed to a $385 million settlement related to the 2022 shutdown of its Sturgis, Michigan baby-formula plant, the largest in the United States. The plant’s problems triggered a…
- FDA seeks external input on rare disease trial criteria and endpoint selectionThe FDA announced it will seek additional external feedback as it reviews how to evaluate efficacy and safety data for rare disease therapies. The agency noted the difficulty of setting appropriat…